Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

SuperGen acquires marketing rights for Barr generic drugs

Aug. 16, 1996

SS Pharm. discloses antitumor platinum complexes

Aug. 16, 1996

NCI supports clinical testing of MGI-114

Aug. 16, 1996

NCI begins pediatric study of carboplatin/RMP-7 combination

Aug. 16, 1996

FDA approves new formulation of Gensi Laboratories' etoposide

Aug. 9, 1996

Water-soluble prodrug of pancratistatin synthesized by Arizona State University

Aug. 9, 1996

Mylan to market generic Taxol in 3 countries

Aug. 9, 1996

RPR seeks approval of Campto in 13 European countries

Aug. 9, 1996

Aryl-ureido anticancer agents reported by Universite Laval

Aug. 9, 1996

Ethyol available on Canadian market

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.